Alterity Therapeutics Ltd has released a press release.
Positive ATH434 Phase 2 Results Led By Clinical Efficacy
Filed with ASX ·
6ix hasn’t read this filing yet.
Alterity Therapeutics Ltd. on 6ix
In the deck
Earlier from Alterity Therapeutics
- Alterity Announces Completion of Phase 2 Clinical Trial
- Appendix 4E Preliminary Final Report
- Positive Interim Data from ATH434-202 Phase 2 Clinical Trial
- Alterity Receives a $3.9 million R&D Tax Incentive Refund
- Alterity Therapeutics Raises $3.25 M AUD in Placement
Later from Alterity Therapeutics
- Alterity Raises Funds for ATH434 BD and Clinical Activities
- Alterity raises A$40m to Advance ATH434 Development in MSA
- Alterity Completes Last Patient Visit in Open-Label Trial
- Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
- Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics